Sunshine Heart Provides Business Update Regarding Execution of Strategic Growth Plan

EDEN PRAIRIE, Minn., March 23, 2017 -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today its progress in successfully executing its Aquadex growth strategy. After acquiring the Aquadex business from Baxter International in August of 2016, the company began executing a revenue growth strategy focused on increasing utilization in the top 55 hospital accounts, which made up 80% of the business. By the end of 2016, there were 95 hospital accounts that have re-engaged and are purchasing the disposable blood sets on a regular basis. As of March 2017, there are now 115 active hospital accounts.
 
“Our momentum is increasing as we reach more hospital accounts that have been quiet over the past few years,” said John Erb, Chairman of the Board and CEO of Sunshine Heart.
Read more: Sunshine Heart Inc ( SSH )

GeneNews Announces Contract with Large Multi-Specialty Physician Group For Use of Early Cancer Diagnostic Tests

Medical Group will be first in U.S. to offer BreastSentry® diagnostic test
 
TORONTO, March 16, 2017  - GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announced today that it has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests. The contract represents the second partnership agreement with a U.S. healthcare services group and will mark the introduction of GeneNews' BreastSentry® diagnostic test to the U.S. market.
Read more: GeneNews Limited ( GEN )

Cesca Therapeutics Highlights Promising Data for the Treatment of Chronic Non-Healing Ulcers

RANCHO CORDOVA, Calif., March 15, 2017  -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced encouraging data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers.
 
Results from the 24 patient study entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series” were published in the peer-reviewed, Journal of Biomedical Science. The study was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute.
Read more: Cesca Therapeutics ( KOOL )

Corindus Announces Partnership with WakeMed Health & Hospitals

Leading cardiovascular hospital to develop vascular robotics program, improve patient care using the CorPath® GRX System
 
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) today announced that WakeMed Health & Hospitals will partner with Corindus to develop a national center of excellence to advance patient care and clinical robotics research and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions ("PCI") using the CorPath GRX System. WakeMed Health & Hospitals is the leading provider of health and cardiovascular services in Wake County, North Carolina.
Read more: Corindus Vascular Robotics ( CVRS )

U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

TORONTO, ONTARIO--(March 7, 2017) -Spectral Medical Inc. ("Spectral" or the "Company")(TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it has received approval of the third module of its rolling PMA submission from the United States Food and Drug Administration ("FDA) for Toraymyxin™. The third PMA module details the device description and principles of operation and all manufacturing processes, including risk management and quality system integration.
 
"We are very encouraged with the FDA's response and approval of the third module. This follows our announcement on February 23, 2017, that we plan to file our fourth and final module containing clinical data early in the second quarter of this year," stated Dr. Paul Walker, President and CEO of Spectral. "The acceptance of the third PMA module by the FDA is another step forward on our regulatory pathway."
Read more: Spectral Medical Inc ( EDT )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker